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Abstract
Background National guidelines recommend trastuzumab
for treatment of patients with metastatic HER2-positive
gastric cancer (GC). There is currently no guideline indi-
cating the number of biopsy specimens and the location
from which they should be obtained to reliably determine
the human epidermal growth factor receptor 2 (HER2)
status in GC. The aim of this pilot study was (a) to quantify
HER2-positive tumor cells in different tumor regions to
assess the spatial heterogeneity of HER2 expression and
(b) to establish the required number of biopsy specimens
and the location from which they should be obtained within
the tumor to achieve concordance between HER2
expression status in the biopsy specimens and the resection
specimen.
Methods HER2 expression was quantified in six different
regions of 24 HER2-positive GC and in six virtual biopsy
specimens from different luminal regions. Intratumoral
regional heterogeneity and concordance between HER2
status in the biopsy specimens and the resection specimen
were analyzed.
Results HER2-positive cells were more frequent in the
luminal tumor surface compared with deeper layers
(p\ 0.001). GCs with differentiated histological features
were more commonly HER2 positive (p\ 0.001).
Assessment of HER2 expression status in five biopsy
specimens was sufficient to achieve 100 % concordance
between the biopsy specimens and the resection specimen.
Conclusions This is the first study to suggest preferential
HER2 positivity at the luminal surface in GC and to
establish a minimum number of biopsy specimens needed
to obtain a biopsy HER2 result which is identical to that
from the whole tumor. Our study suggests that HER2
testing in five tumor-containing endoscopic biopsy speci-
mens from the proximal (oral) part of the tumor is advis-
able. The results from this pilot study require validation in
a prospective study.
Keywords HER2 expression  Gastric cancer  Virtual
biopsy
Introduction
Gastric cancer (GC) incidence has been steadily declin-
ing in recent decades, but GC remains the fifth com-
monest cancer globally and the second commonest
cancer in Japan [1]. GC patients with inoperable,
& Naoyuki Tominaga
takujigotoda@yahoo.co.jp
& Heike I. Grabsch
heike.grabsch@mumc.nl
1 Department of Gastroenterology and Hepatology, Tokyo
Medical University, Tokyo, Japan
2 Departments of Internal Medicine and Gastrointestinal
Endoscopy, Saga Medical School, Saga, Japan
3 Department of Preventive Medicine, Faculty of Medicine,
Saga Medical School, Saga, Japan
4 Section of Pathology and Tumour Biology, Leeds Institute of
Cancer and Pathology, University of Leeds, Leeds, UK
5 Department of Pathology, Tokyo Medical University, Tokyo,
Japan
6 Department of Pathology, Maastricht University Medical
Center, P. Debyelaan 25, 6202 AZ Maastricht,
The Netherlands
7 GROW School for Oncology and Developmental Biology,
Maastricht University Medical Center, Maastricht,
The Netherlands
123
Gastric Cancer (2016) 19:553–560
DOI 10.1007/s10120-015-0502-3
metastatic or recurrent disease have very poor survival
even after palliative cytotoxic chemotherapy [2]. The
ToGA trial demonstrated that trastuzumab therapy in
combination with cytotoxic chemotherapy significantly
improved survival of patients with human epidermal
growth factor receptor 2 (HER2)-positive GC [3]. Since
then, trastuzumab has been licensed in Europe [4] and
the USA and other countries for use in HER2-positive
metastatic GC [5].
With the exception of patients with recurrent disease
after previous resection, the HER2 status is usually de-
termined using endoscopic biopsy specimens. GC-speci-
fic HER2 scoring guidelines have been established
recently, detailing that a GC biopsy specimen with
complete, basolateral or lateral membranous immunore-
activity in more than five ‘‘clustered tumor cells’’ is
classified as HER2 positive [6]. However, the same
HER2 guidelines are vague regarding the number of
biopsy specimens, the tumor content per biopsy speci-
men, or the location from which the biopsy specimen
should be obtained within the tumor, and simply rec-
ommend that ‘‘an adequate number of viable biopsy
specimens (ideally six to eight) are required.’’ The cur-
rent guidelines do not provide any evidence for the
recommendations made and do not seem to consider the
suggested relationship between HER2 positivity and
histological subtype, grade of differentiation [7–11], and
tumor location [12] in GC.
The reported concordance of GC HER2 expression be-
tween endoscopic biopsy specimens and resection material
ranges widely from 45.5 to 88.5 % [13, 14]. Investigators
have mostly provided only very little or no information at
all on the resection and/or biopsy material used, and have
concluded that this variability is due to ‘‘intratumoral
heterogeneity’’ [15] without providing a definition of this
term.
We hypothesized (a) that HER2-positive tumor cells
have no preferential spatial distribution within a given
GC and (b) that a high concordance of the HER2 status
between biopsy specimens and the resection specimen
can be achieved with six tumor-containing biopsy spe-
cimens. We decided on six biopsy specimens on the
basis of the ideal number of biopsy specimens mentioned
above.
To test the above-mentioned hypotheses, we (a) quanti-
fied HER2-positive tumor cells in six different regions in
gastric resection specimens to measure the spatial HER2
expression heterogeneity and (b) assessed HER2 expres-
sion status in six virtual biopsy specimens from different
luminal locations within the tumor to calculate the con-
cordance rate between biopsy specimen and resection
specimen HER2 status.
Materials and methods
Eighty-four patients were treated by gastrectomy for gas-
tric adenocarcinoma at the Tokyo Medical University be-
tween 2011 and 2013. In all cases, the tumor was sampled
from anal to oral, including the deepest tumor infiltration,
at the time of cutting up the specimen according to our
routine laboratory protocol [16].
HER2 expression was investigated in tumor blocks per
case using immunohistochemistry (HercepTest II, Dako,
Japan) according to the instructions of the manufacturer
and using previously published scoring criteria [17]. The
tumor slice with the deepest tumor invasion was used for
this study. Depending on the tumor size, this slice was
embedded in one or more cassettes. The maximum number
of cassettes required to completely embed the tumor slices
with the deepest invasion was six.
Twenty-four GCs were classified as HER2 positive on
the basis of immunohistochemistry (HER2 scores of 2?
and 3?) and were included in the current study. HER2
copy number was not assessed.
The macroscopic tumor type was classified according to
the Japanese classification of GC [16]. The depth of inva-
sion (T category) and the lymph node status (N category)
were classified using the seventh edition of the Union for
International Cancer Control TNM classification [18]. The
histological tumor type was classified using the Japanese
classification and the Lauren classification [16, 18].
For the assessment of the spatial heterogeneity of HER2
expression in the tumor, every tumor was divided into three
regions of equal length designated as ‘‘oral’’ [i.e., from the
oral (proximal) tumor edge to the central part of the tumor],
‘‘central’’ (i.e., the central part of the tumor), and ‘‘anal’’
[i.e., from the central part of the tumor to the anal (distal)
tumor edge]; see Fig. 1. The median length of the each
individual region was 14.7 mm, ranging from 5 to 40 mm.
Each tumor region was further divided into a luminal layer
measuring 2 mm from the luminal tumor surface into the
wall and a deeper layer comprising all tumor beyond the
2-mm depth limit; see Fig. 1. A 2-mm cutoff was chosen as
this is the depth that can be sampled by routine endoscopic
biopsy (disposable biopsy forceps, Olympus, Japan). The
histological tumor type was determined for each region
separately. The percentage of HER2-positive tumor cells
was established for each region by assessing 200 tumor
cells in ten randomly selected areas per region—that is, by
assessing a total of 2000 tumor cells per region and up to a
total of 12,000 tumor cells per case.
To assess the concordance of the HER2 status and the
histological subtype between biopsy specimens and the
resection specimen, we collected data from six circles
measuring 2 mm in diameter (‘‘virtual’’ biopsy specimens)
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from the luminal layer of the hematoxylin and eosin stained
slide and from the matched HER2-stained slide. Two vir-
tual biopsy specimens were taken from the oral region, two
were taken from the central region, and two were taken
from the anal region from each tumor; see Fig. 2. The
percentage of HER2-positive tumor cells in the virtual
biopsy specimens was determined by assessing all tumor
cells present in the biopsy specimen.
Statistical analyses
A tumor was defined as being ‘‘heterogeneous’’ with re-
spect to the histological subtype if two or more tumor re-
gions showed a different histological subtype, and as being
heterogeneous for HER2 expression if two or more tumor
regions had a significantly different percentage of HER2-
positive tumor cells.
Fig. 1 The division of the
tumor into six parts. The tumor
was divided equally into three
regions—oral region (O),
central region (M), and anal
region (A)—which were each
divided in turn into an upper
layer (LUM) and a lower layer
(DEEP)
Fig. 2 The ‘‘virtual biopsy.’’ We marked six positions on the
prepared slide by a double-blind method: two were on the surface
of the oral region (O), two were on the surface of the central region
(M), and two were on the surface of the anal region (A). The black
dots in the image at the bottom right indicate the tumor range (the
tumor area was inside). The virtual biopsy sites are indicated by white
circles. HE hematoxylin and eosin, HER2 human epidermal growth
factor receptor 2
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To calculate the concordance rate between the biopsy
specimens and the whole tumor, the percentage of HER2-
positive cells in the biopsy specimens was cumulatively
compared with the percentage of HER2-positive cells in
the whole tumor. Thus, the percentage of HER2-positive
cells in the first biopsy specimen was compared with that in
the whole tumor, and then the percentage of HER2-positive
cells in the first and second biopsy specimens, the per-
centage of HER2-positive cells in the first, second, and
third biopsy specimens, etc. We also assessed whether the
concordance rate between the biopsy result and whole tu-
mor result was dependent on the region from which the
biopsy specimen was taken.
Using the HER2 expression status of individual virtual
biopsy specimens, we analyzed the number of biopsy spe-
cimens required to diagnose ‘‘HER2positivity.’’ The ‘‘HER2
expression ratio’’ (see Fig. 3) was calculated using prob-
ability statistics by calculating the number of combinations
of n objects taken r at a time:C(n,r) = n!/[r!(n - r)!]. In this
formula, the shorthand notation of n! (i.e., n factorial) is used.
The denominator of the HER2 expression ratio was C(6,r0),
and the numerator of the HER2 expression ratio wasC(n0,r0).
n0 is the number of HER2-positive virtual biopsy specimens
in the case, and r0 is the number of biopsy specimens dis-
played on the x-axis of Fig. 3.
The v2 test, the Mann–Whitney U test, and Holm’s test
were used for categorical variables, continuous variables,
and multiple comparisons, respectively. A p value of less
than 0.05 was considered significant. Statistical analyses
were performed using R (version 2.12.2).
Results
Patient characteristics
The patient and tumor characteristics of the study popula-
tion are shown in Table 1. The median age was 71 years
(range 53–84 years). The median tumor length from anal to
oral was 44 mm (range 15–120 mm), from anterior to
posterior was 30 mm (range 11–75 mm), and from luminal
to deepest tumor infiltration in the wall was 8 mm (range
2–23 mm). The tumor was ulcerated in 16 patients (67 %).
Heterogeneity of histological subtype
Seven GCs (29 %) showed an identical histological
subtype in all regions and all biopsy specimens and were
therefore classified as homogenous. Six of these were
Fig. 3 Human epidermal growth factor receptor 2 expression ratio
related to the number of biopsy specimens
Table 1 Patient and tumor characteristics
Tumor location Number of patients Percentage of patients
Upper third 7 29.2
Middle third 9 37.5
Lower third 8 33.3
Depth of invasion (pT)
T1 13 54.2
T2 3 12.5
T3 3 12.5
T4 5 20.8
Lymph node status (pN)
N0 10 41.7
N1 5 20.8
N2 5 20.8
N3 4 16.7
Ulceration
With 16 66.7
Without 8 33.3
TNM stage
I 12 50
II 6 25
III 5 20.8
IV 1 4.2
Heterogeneity of histological subtype
Homogeneous 7 29.2
Intestinal type 6 25
Diffuse type 1 4.2
Heterogeneous 17 70.8
Luminal layer
Homogeneous 9 37.5
Intestinal type 8 33.3
Diffuse type 1 4.2
Heterogeneous 15 62.5
Deeper layer
Homogeneous 10 41.7
Intestinal type 6 25
Diffuse type 4 16.7
Heterogeneous 14 58.3
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classified as intestinal-type GC and one was classified as
diffuse-type GC. When histological subtype heterogeneity
was assessed by comparing layers (luminal vs deep), nine
GCs (38 %) were classified as homogenous in the lumi-
nal layer, eight of which were intestinal-type GC and one
of which was diffuse-type GC. Ten GCs (42 %) were
classified as homogenous in the deeper layer, six of
which were intestinal-type GC and four of which were
diffuse-type GC. This suggests that the observed hetero-
geneity of the histological subtype may be related to the
depth of invasion.
Concordance of histological subtype between biopsy
specimens and the resection specimen
Two biopsy specimens were taken from each luminal re-
gion—that is, six biopsy specimens per case. The results
are shown in Table 2. In total, 19 biopsy specimens (13 %)
were uninformative as they did not contain any tumor cells
(eight, five, and six specimens from oral, central, and anal
regions, respectively). In 23 GCs (96 %), the two biopsy
specimens taken from the same region showed the same
histological subtype, and in eight GCs (33 %), all six
biopsy specimens showed the same histological subtype.
In the luminal oral region, 13 GCs (54 %) were classi-
fied as intestinal-type GC and one GC (4 %) was classified
as diffuse-type GC by both biopsy specimens and region
(concordance rate 58 %). In the luminal central region, ten
GCs (42 %) were classified as intestinal-type GC and five
GCs (21 %) were classified as diffuse-type GC by both
biopsy specimens and region (concordance rate 63 %). In
the luminal anal region, 11 GCs (46 %) were classified as
intestinal-type GC and one GC (4 %) was classified as
diffuse-type GC by both biopsy specimens and region
(concordance rate 50 %).
Heterogeneity of HER2 expression
The median percentage of HER2-positive tumor cells was
41.1 % (range 2.0–74.2 %), 34.0 % (range 0.0–90.7 %),
30.8 % (range 0.0–99.7 %), and 13.5 % (range 0.0–98.0 %)
per case, layer, region, and biopsy specimen, respectively.
Twenty-three GCs (96 %) had HER2-positive tumor cells
in all luminal regions. The remaining one had HER2-posi-
tive tumor cells in the two lateral regions and had no HER2-
positive tumor cells in the central region because of the
presence of an ulceration. Five GCs (21 %) had no HER2-
positive tumor cells in the deeper regions. The percentage of
Table 2 The results of virtual
biopsies
Quality of biopsy specimens Number of patients Percentage of patients
Informative biopsy specimens
Oral 40 83.3
Central 43 89.6
Anal 42 87.5
Uninformative biopsy specimens
Oral 8 16.7
Central 5 10.4
Anal 6 12.5
Concordance of histological subtype between biopsy specimen and region
Same 23 95.8
Different 1 4.2
Concordance of histological subtype between six biopsy specimens
Same 8 33.3
Different 16 66.6
Histological subtype by both biopsy specimens and region
Oral
Intestinal type 13 54.2
Diffuse type 1 4.2
Central
Intestinal type 10 41.7
Diffuse type 5 20.8
Anal
Intestinal type 11 45.8
Diffuse type 1 4.2
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HER2-positive tumor cells was significantly different
among regions in all GCs, and therefore all GCs were
classified as heterogeneous for HER2 expression.
The percentage of HER2-positive tumor cells was sig-
nificantly higher in the luminal layer than in the deeper
layer [median percentage of HER2-positive tumor cells in
the luminal layer of 60.3 % (range 3.9–90.7 %) vs 21.7 %
(range 0.0–67.2 %) for the deeper layer; p\ 0.001]. For
the three different regions within the luminal layer, the
percentage of HER2-positive tumor cells was higher in the
lateral (anal and oral) regions than in the central region,
although this did not reach statistical significance [median
percentage of HER2-positive cells in the luminal anal re-
gion of 58.3 % (range 4.3–92.2 %) vs 65.0 % (range
4.2–99.7 %) for the luminal oral region and 57.2 % (range
0.0–95.0 %) for the luminal central region; p = 0.98].
The median percentage of HER2-positive tumor cells in
the virtual biopsy specimens was highest in the oral region
and lowest in the anal region [median percentage of HER2-
positive cells in the oral region was 34.5 % (range 0–98 %)
vs 11.5 % (range 0–91 %) in the central region and 0 %
(range 0–98 %) in the anal region; p = 0.027 (oral vs
central) and p = 0.020 (oral vs anal)].
Concordance of HER2 expression between biopsy
specimens and the resection specimen
Two biopsy specimens were taken from each luminal re-
gion—that is, six biopsy specimens per case. For the
HER2-stained slides, 19 biopsy specimens (13 %) were
uninformative as they did not contain any tumor cells
(eight, five, and six specimens from oral, central, and anal
regions, respectively). In 12 GCs (50 %), the two biopsy
specimens taken from the same region showed a difference
in the percentage of HER2-positive cells of over 87.2 %.
Only two GCs (8 %) showed no significant difference in
the percentage of HER2-positive tumor cells in all six
biopsy specimens.
The concordance of the percentage of HER2-positive
tumor cells between biopsy specimens and the resection
specimen is shown in Table 3. In 17 GCs (71 %), 16 GCs
(67 %), and 13 GCs (54 %), the percentage of HER2-
positive cells in either one or two biopsy specimens from
the luminal oral, central, or anal region, respectively, was
not significantly different from the percentage of HER2-
positive cells from the whole region of origin. In 12 GCs
(50 %), 9 GCs (38 %), and 6 GCs (25 %), the percentage
of HER2-positive cells in both biopsy specimens from the
luminal oral, central, or anal region, respectively, was not
significantly different from the percentage of HER2-posi-
tive cells in the region of origin. In 19 GCs (79 %), 19 GCs
(79 %), and 15 GCs (63 %), the percentage of HER2-
positive cells in either one or two biopsy specimens from
the luminal oral, central, or anal region, respectively, was
not significantly different from the percentage of HER2-
positive cells in the whole tumor. In 12 GCs (50 %), 10
GCs (42 %), and 6 GCs (25 %), the percentage of HER2-
positive cells in the both biopsy specimens from the lu-
minal oral, central, or anal region, respectively, was not
significantly different from the percentage of HER2-posi-
tive cells in the whole tumor. The concordance rate be-
tween the percentage of HER2-positive cells in the biopsy
specimens and the percentage of HER2-positive cells in the
whole tumor was highest (79 %) when biopsy specimens
were obtained from the oral region and was lowest (63 %)
when the anal region was sampled.
Table 3 The concordance of
the percentage of human
epidermal growth factor
receptor 2 expression between
biopsy specimens and the
resection specimen
Number of patients Percentage of patients
One or two biopsy specimens from the region versus the whole region
Oral 17 70.8
Central 16 66.7
Anal 13 54.2
Both biopsy specimens from the region versus the whole region
Oral 12 50.0
Central 9 37.5
Anal 6 25.0
One or two biopsy specimens from the region versus the whole tumor
Oral 19 79.2
Central 19 79.2
Anal 15 62.5
Both biopsy specimens from the region versus the whole tumor
Oral 12 50.0
Central 10 41.7
Anal 6 25.0
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Relationship between histological subtype
and HER2 expression per region
On the basis of the resection specimen, 22 HER2-positive
GCs (92 %) were classified as intestinal-type GC and two
(8 %) were classified as diffuse-type GC (p\ 0.001)
HER2 expression per tumor region
HER2-positive cells were counted for all regions separately
and compared between regions. Luminal regions had sig-
nificantly more HER2-positive cells than deeper regions
(p\ 0.001; Fig. 4), and lateral parts of the tumor (round
wall side ‘‘O’’ and ‘‘A’’) tended to have more HER2-
positive cells than central regions.
Estimation of the number of biopsy specimens
needed for reliable HER2 testing based on ‘‘virtual
biopsy’’ specimens
The proportion of HER2-expressing GCs detected by using
different numbers of biopsy specimens is shown in Fig. 3.
Although the ideal number of biopsy specimens was more
than six, HER2 expression was detected in all GCs for five
or more biopsy specimens.
Discussion
The recent ToGA trial showed that the addition of
trastuzumab therapy to chemotherapy significantly im-
proves survival of patients with HER2-expressing
advanced or metastatic GC, underscoring the importance to
accurately identify patients eligible for this treatment [3].
However, reported rates of HER2 positivity differ consid-
erably in the current GC literature [19, 20].
In this pilot study, we used material from previously
classified HER2-positive GC resection specimens to
quantitatively and qualitatively assess the heterogeneity of
the histological subtype and HER2 expression in different
regions of the tumor to identify the minimum number of
biopsy specimens needed to achieve the highest concor-
dance between biopsy specimen and resection specimen
HER2 status. HER2-expressing tumor cells were prefer-
entially located in the luminal lateral layer of the tumor,
which coincides with the location of the well-differentiated
tumor cells. Poorer differentiation in deeper layers has been
described previously in GC [21]. It has been described
previously that ulcerated central tumor areas were usually
HER2 negative and should be avoided when sampling tu-
mors endoscopically. Our virtual biopsy study indicates
that five tumor-containing biopsy specimens are sufficient
to have the same HER2 expression status as in the resection
specimen. This supports the recommendation of the Na-
tional Comprehensive Cancer Network guidelines for more
than six biopsy specimens in order to diagnose HER2 ex-
pression in GC.
HER2 expression was detected in all cases by taking five
biopsy specimens from the tumor, and the oral region seems
to be the ‘‘optimal’’ location for sampling to determine the
HER2 status in GC with a high level of confidence.
In conclusion, this is the first study that has demon-
strated and quantified spatial heterogeneity of HER2 ex-
pression in GC and showed preferential expression of
HER2 in the luminal and lateral parts of the tumor, sup-
porting the validity of using endoscopic biopsy samples for
HER2 testing. The preferential location of HER2-positive
tumor cells coincided with the preferential location of well-
differentiated tumor cells in GC. The achievable high
concordance between HER2 biopsy specimen and resection
specimen status for a minimum of five tumor-containing
biopsy specimens is encouraging. We are aware that this is
a retrospective study in a relatively small number of spe-
cimens, and thus a larger prospective study is required to
confirm the findings from our pilot study before guidelines
can be issued on endoscopic sampling of GCs for HER2
testing.
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Fig. 4 The result of Holm’s test for cells expressing human
epidermal growth factor receptor 2 which were counted individually.
A anal region, DEEP deeper layer, LUM luminal layer, M central
region, O oral region
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